BioCentury
ARTICLE | Product Development

ACTIV coming into focus, starting COVID-19 therapy trials in June

NIH’s ACTIV consortium plans to start studying COVID-19 therapies in June

June 13, 2020 3:05 AM UTC

A consortium that is pooling the resources of the U.S. government and global biopharmaceutical companies to discover and develop drugs and vaccines for COVID-19 has selected a first wave of therapies for testing and plans to start two Phase III master protocols this summer, according to documents obtained by BioCentury.

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership, will start its first trials in June on repurposed immune-modulators and anticoagulants. ...